Vanguard Global Advisers
KROS icon

Vanguard Global Advisers’s Keros Therapeutics KROS Stock Holding History

Vanguard Global Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85K Sell
7,945
-7,810
-50% -$87K ﹤0.01% 2848
2026
Q1 		$174K Buy
+15,755
New +$243K ﹤0.01% 2499

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Global Advisers's KROS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Keros Therapeutics (KROS) stake by 50% in Q2 2026, selling an estimated $87K and leaving 7,945 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Vanguard Global Advisers first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $174K in Q1 2026. 129 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Vanguard Global Advisers held 7,945 shares of Keros Therapeutics worth $85K as of Q2 2026.
  • Vanguard Global Advisers sold 7,810 Keros Therapeutics shares in Q2 2026, an estimated $87K.
  • Keros Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2848 holding.
  • Vanguard Global Advisers first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Keros Therapeutics position peaked at $174K in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.